At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension
In Brief
A Phase 2 clinical trial evaluating sacubitril/valsartan (LCZ696), olmesartan, and 3 other interventions for Hypertension. Completed, enrolled 115 participants across 4 sites in 3 countries.
Detailed Summary
This was the first evaluation of the effects of LCZ696 on local and regional measures of aortic stiffness in subjects with mild to moderate hypertension and widened pulse pressure. The results of this exploratory study will help to understand the mechanism of action of LCZ696 and used to inform the design of future clinical studies with LCZ696 in subjects with cardiovascular diseases.
Study Details
Timeline
Interventions
200 mg tablets
placebo
placebo
If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen